Abstrakt

A FGFR-2 Inhibitor, Ki23057, Evaluated as a Novel VEGFR-2 Kinase Inhibitor

Zong-Shan Ma, Qiang-wen Fan, Hong Yan and Da-Hai Yu

The aim of this study was to clarify the ability of a FGFR-2 inhibitor, Ki23057, to inhibit the VEGFR-2 signaling pathway which was a valuable approach in the treatment of cancers. An efficient and convenient synthetic route to Ki23057 has been developed utilizing a key onepot method. Its biological activities as VEGFR-2 kinase inhibitors were evaluated by immunohistochemistry. The results exhibited that the Ki23057 has potent inhibitory activities against VEGFR-2 tyrosine kinase. Docking simulation was performed to demonstrate that Ki23057 is a potential agent for VEGFR-2 cancer therapy.